Precision Medicine for L/GCMN and Melanoma 2
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorFundacion Clinic per a la Recerca Biomédica
About this trial
The primary objective is to evaluate the possibility of using minimally and non-invasive technologies (skin patch and breath analyzer) based on the detection of volatile organic compounds (VOCs) for the early identification of metastases. The secondary objective is to evaluate the usability of these technologies in the follow up of high-risk melanoma patients.
Eligibility criteria
Qualifiers
Be over 18 years old
Have a histopathological confirmed melanoma diagnosis (stage II, III or IV AJCC)
Disqualifiers
Not signing the informed consent form
Present other cancers or chronic diseases (such as diabetes, asthma, etc.), which may affect the volatile organic compound profiles
Trial design
Treatments tested in this trial
- Breath analyzer
- Skin patch
- Liquid biopsy
Treatment groups
100 Participants
are divided into 2 treatment groupsSponsors and collaborators
Fundacion Clinic per a la Recerca Biomédica
Lead sponsor
Hospital Clinic of Barcelona
Collaborator
Source ClinicalTrials.gov